Just Diagnosed

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

[powerpress]

Dr. Karen Kelly, of the University of California, Davis, provides her thoughts on whether to continue an effective treatment beyond 4-6 cycles in an effort to exhaust the possible benefit from that treatment.

[powerpress]

David Spigel, Sarah Cannon Cancer Center, reviews how he discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.

[powerpress]

Dr. Sarah Goldberg, from Yale Cancer Center, offers her insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.

[powerpress]

Dr. Lecia Sequist of Massachusetts General Hospital, discusses the concept of multiplex next generation sequencing and how it could change molecular oncology.

[powerpress]

Dr. Rosalyn Juergens, McMaster University, addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with that information if it is available for potential use in the adjuvant setting.

[powerpress]

Dr. Greg Riely, from Memorial Sloan-Kettering, reviews his thought process in recommending a repeat biopsy at initial diagnosis or after progression for patients with advanced lung cancer.

[powerpress]

Drs. Ross Camidge and Corey Langer give their views on more widespread availability of new mutation tests.

[powerpress]

Dr. Phil Bonomi, from Rush University, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.

[powerpress]

Dr. Karen Kelly of the University of California, Davis, provides her view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

[powerpress]